BRAF and neoplasm: This mutation leads to a conformational change in the BRAF protein, over-activating the downstream kinases MEK1/2-ERK1/2, which in turn activates a series of genes related to cell proliferation and enhanced metabolism, and promotes tumor growth and metastasis (Haling et al., 2014).